How it works:
Olaparib blocks the PARP enzyme involved in repairing damaged DNA. In BRCA-mutated cancer cells, this mechanism leads to cell death due to faulty DNA repair. It is a key part of precision medicine for patients with inherited or resistant tumours.
Recommended for:
Women with relapsed high-grade ovarian carcinoma with BRCA mutations
Patients with HER2-negative BRCA-related breast cancer
Men with metastatic castration-resistant prostate cancer
As maintenance therapy after response to platinum-based chemotherapy
High-grade BRCA-positive ovarian cancer
Metastatic BRCA-mutated breast cancer
Advanced prostate cancer linked to DNA repair dysfunction
Maintenance treatment in platinum-responsive patients
Swallow the tablets whole, with or without food, as prescribed by your oncologist. Dosage and duration depend on clinical response and tolerability. Liver, kidney and blood function should be regularly monitored during therapy.
Hypersensitivity to olaparib or formulation ingredients
Pregnancy and lactation
Severe hepatic or renal impairment
Paediatric patients
History of myelodysplastic syndrome or acute myeloid leukaemia
Haematological: anaemia, neutropenia, thrombocytopenia
Gastrointestinal: nausea, vomiting, dyspepsia
General: fatigue, headache
Metabolic: increased serum creatinine
Hypersensitivity or skin reactions
Rare: interstitial lung disease
